Brazilian Pharmaceutical Market 2014-2024

Description

Brazilian Pharmaceutical Market 2014-Brazilian Pharmaceutical Market 2014- 2024 PR Newswire LONDON, November 26, 2013 Drug selling in Brazil - this new analysis shows you trends, opportunities, and revenues Do you want to assess the future of pharmaceuticals in Brazil? See what lies ahead, then. Visiongain's new report gives you revenue predictions, helping your work. There you discover financial results, trends, opportunities, and sales forecasts. So you see what's possible for that trade. Get data to 2024 for the drugs industry operating there. You find business analysis, trends, prospects, and potential revenues. Read on to explore Brazilian drug sales and see what they could be worth in future. Trends and outlooks for that developing country - find how you can benefit Our study concludes that - from 2014 - patients, healthcare providers and pharma companies will benefit from progress in Brazil. You discover where, how, and why. There you find trading predictions from 2013 to 2024 at overall national and submarket levels. You hear where the money lies. Also save time. See how you can help your research, analyses, and decisions. That way you could gain more influence and recognition. Forecasts and other data to help you find the most lucrative possibilities To support our forecasting, our work shows you historical data, recent results, growth rates, and market shares. There you investigate developments and potentials, finding what they mean and their values.

Informations

• Publié par: visiongain
• Publié le: 26 novembre 2013
• Nombre de lectures: 6
• Langue: English

Extrait

Brazilian Pharmaceutical Market 2014-2024

PR Newswire

LONDON, November 26, 2013

Drug selling in Brazil - this new analysis shows you trends, opportunities, and revenues

Do you want to assess the future of pharmaceuticals in Brazil? See what lies ahead, then. Visiongain's new report gives you revenue predictions, helping your work. There you discover financial results, trends, opportunities, and sales forecasts.

So you see what's possible for that trade. Get data to 2024 for the drugs industry operating there. You find business analysis, trends, prospects, and potential revenues.

Read on to explore Brazilian drug sales and see what they could be worth in future.

Trends and outlooks for that developing country - find how you can benefit

Our study concludes that - from 2014 - patients, healthcare providers and pharma companies will benefit from progress in Brazil. You discover where, how, and why.

There you find trading predictions from 2013 to 2024 at overall national and submarket levels. You hear where the money lies. Also save time. See how you can help your research, analyses, and decisions. That way you could gain more influence and recognition.

Forecasts and other data to help you find the most lucrative possibilities

To support our forecasting, our work shows you historical data, recent results, growth rates, and market shares. There you investigate developments and potentials, finding what they mean and their values. You also get 61 tables and 47 charts. So avoid falling behind.

Information on medical commerce in Brazil just got easier to find. And the following sections show you what our investigation gives.

Potentials of medicines in Brazil - national trade forecasting overall and by segment

What're the secrets of that market's progress? What's Brazil's potential? Our study gives you feel for that emerging nation's pharma needs and prospects.

So you discover overall drug revenues there to 2024, with discussions. Our report also shows individual sales predictions - from 2013 to 2024 - for nine submarkets:
• Patented therapies - small-molecule prescription (Rx) agents and biological drugs (biologics)
• Generic pharmaceuticals (generics)
• Over-the-counter (OTC) medicines.

And also for these therapeutic applications, via another market breakdown:
• Central nervous system (CNS) products
• Cardiovascular (CV) diseases treatment
• Alimentary and metabolic disorders therapy
• Cancer treatments (oncology)
• Infectious diseases - anti-infective agents (vaccines and antibiotics)
• Therapies for other illnesses.

How will those sectors expand? Which classes of treatment and therapeutic areas will yield most money? There you assess commercial outlooks, seeing where you can gain.

You also investigate what stimulates and restrains those submarkets.

Issues and events - what affects developers, producers, and sellers of medicines in Brazil?

Our report also discusses forces shaping pharma there from 2013 to 2024, including these:
• Strategies companies and healthcare providers use to serve that country's needs, as well as technologies (inc. R&D) and strategic advantages
• Contributions of domestic and foreign companies, inc. their entry
• Demographic trends and governmental policies, inc. pricing and regulations
• Efforts by regions to improve medical provision, better serving patients
• Brazil's position in Latin American, BRIC nations, and world pharma business.

There you examine political, economic, social, and technological questions, assessing commercial outlooks. Explore what stimulates and restrains drug developers and makers.

You see, then, what affects participants in that industry and you find its potential.

Analysis of top companies and their industry's performance - what results possible?

What happens next? Our work predicts the Brazilian pharma market will reach $41.3bn in 2017 - with fast expansion - and by 2024 contribute strongly to world medical revenues.

You discover what causes that rise. First, the study explains activities of 12 leading domestic companies, in particular, including these firms:
• EMS
• Medley
• Hypermarcas
• Aché
• Eurofarma.

You also assess 17 multinational (big pharma) organisations, inc. these corporations:
• Sanofi
• Novartis
• Roche
• Pfizer
• Merck & Co.

Discover the efforts of specialists too, including firms making biopharmaceuticals.

Developments of leading generics and biosimilar manufacturers

In the report you also review international producers and marketers of generics and biosimilars, including these players targeting Brazil:
• Teva
• Sandoz
• Mylan
• Actavis
• Ranbaxy.

From 2014 great progress in Brazilian medical sales will occur. Pharma industry leaders and specialty operations - esp. manufacturers of generic and biosimilar drugs - stand to profit.

Ways Brazilian Pharmaceutical Market 2014-2024  helps you

In particular, then, our new investigation gives you this knowledge:
• Revenues to 2024 at national level and for 9 submarkets - explore prospects for investments, marketing, and sales
• Analyses of what stimulates and restrains medical enterprises there - assess challenges, strengths, and competition affecting participants' strategies
• Prospects for established competitors, rising companies, and new entrants - analyse portfolios, R&D, approvals, collaborations, strategy, and chances of success.

Information found nowhere else, letting you appraise Brazilian pharma activities

Our new report gives independent analysis. There you receive competitive intelligence found only in our work, finding where the money exists. Explore progress and possibilities.

With that report you're less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find there how you could save time and effort, also benefiting your authority.

Predictions for medical businesses in Brazil - help your work now by trying our report

Our new report is for everyone considering emerging pharma markets. Now you can assess one of the most promising countries. So avoid missing out - please order now.

Companies Listed

Abbott Laboratories (including Abbvie)
Achê Laboratórios Farmacêuticos
Actavis
Agência Nacional de Saude Suplementar
Agência Nacional de Vigilância Sanitária (ANVISA)
Agila Specialties
AlfaRio
Alliance Boots
Allianz Health
AMB (Brazilian Medical Association)
American Diabetes Association
American Varian Medical Systems
Amgen
Amil Participações
Antaris Consulting
Arena Pharmaceuticals
Arseus
Associação Brasileira da Indústria de Medicamentos Isentos de Prescrição (ABIMIP)
Associação Brasileira das Redes de Farmácias e Drogarias (ABRAFARMA)
Associação Brasileira de Reabilitação de Coluna
Associacao da Industria Farmaceutica de Pesquisa (InterFarma)
Associação Nacional de Assistencia ao Diabetico (ANAD)
Astellas
AstraZeneca
Athos Pharma
Axis Biotec
Baxter
Bayer
BD
Biocon
Biogen Idec
Biolab Emcure
Biolab-Sanus Farma
Biomm
Bionovis
Biosidus
Biovail Corporation
Boehringer Ingelheim
Boiron
Bradesco Saúde
Brainfarma Industria e Farmaceutica
Brasil Pharma
Brazilian Development Bank (BNDES)
Bristol-Myers Squibb
BTG Pactual
Bunker Industria Farmaceutica
Caixa Seguros
Câmara de Regulação do Mercado de Medicamentos (CMED)
Cannes RJ Participacoes
Castro Marques Group
Celesio
Chemo
Claris Lifesciences
CMED
Comissão Nacional de Incorporação de Tecnologia (CONITEC)
Comitê Técnico Assessor de Imunizações (CTAI)
Conselho Administrativo de Defesa Econômica
Corporacion Infarmasa
CPhI Worldwide
CVS Pharmacy
Daiichi Sankyo
Datamatrix
Delta Instituto Terapeutico
Dimed
Disaq Pharmaceuticals
DM Industria Farmaceutica
Dong-A
DPSP
Drogarias Tamoio
Eisai
Eli Lilly
Emcure
EMS
Eurofarma
Everis
Excel RX
FarmaBrasil group
Farmácia Popular
Farmadacta Informatica
Farmais
Far-Manguinhos
Farmindustria
FDA
Federação Nacional de Saúde Suplementar
Federal Council of Medicine (CFM)
Fiocruz
Food and Drug Administration (US FDA)
Forest Laboratories
GE
Genfar
Genzyme
Germed Pharma
Gilead Sciences
GlaxoSmithKline (GSK)
Glenmark
Golden Cross Assistance
Grünenthal
Grupo Bradesco
Grupo Cimed
Guararapes
Health Canada
Hebron
Hemobrás
Hospital das Clínicas
Hospital Israelita Albert Einstein
Hospital Santa Catarina
Hypermarcas
IMA Laboratories
Indian Council of Medical Research
Infectious Disease Research Institute (IDRI)
Institut Pasteur
Instituto Butantan
Instituto de Estudos de Saúde Suplementar (IESS)
Interagile Propaganda e Promocoes
Intermédica
Itauseg Health
Johnson &?Johnson (J&J)
Kenya Medical Research Institute
Laboratorio Cristália
Laboratório Daudt Oliveira
Laboratório Farmaceutico do Estado de Pernambuco (LAFEPE)
Laboratorio Quimico Farmaceutico Bergamo
Laboratorio Teuto Brasileiro
Laboratorios Gautier
Laboratórios Kendrick
Laboratórios Klinger Do Brasil
Laramara
Legrand
Libbs Farmacêutica
Locafarma Solucoes de Transportes e Logistica
Luper Indústria Farmacêutica
Mais Econômica
Mantecorp Industria Quimica e Farmaceutica
Maritima Seguros
Mayne Pharma
Médecins sans Frontières
Medley
Meizler Biopharma
Melcon
Merck & Co.
Merck Serono
Merz Pharma
Metlife Dental Plans
Minas Gerais State Department of Health
Ministério da Saúde (Ministry of Health, Brazil)
moksha8
Multilab Industria e Comercio de Produtos Farmaceuticos
Mylan
Nature's Plus Farmaceutica
Neo Química
Neuberger Machines
Novartis
Novo Nordisk
Nycomed
Odontoprev Omint Health Services
Oncoprod
Optimer Pharmaceuticals
Orygen Biotecnologia
Oswaldo Cruz Foundation
Otsuka
Pan American Health Organization
Panarello
Panpharma
Pasteur Institute
Pele Nova
Penha
Pfizer
Pharmaceutical Product Development, LLC (PPD)
PharmaPraxis
Porto Seguro
Probiomed
Probiotica
Procter & Gamble
Profarma
Pró-Genéricos
Promovendas Representacoes
Protalix BioTherapeutics
Quesada Farmaceutica
Quintiles
RaiaDrogasil
Ranbaxy
Reckitt Benckiser
Regional Council of Medicine, State of São Paulo
Roche
Rosário
Sabin Vaccine Institute
Sandoz
Sanofi
Sant'Ana
Santa Cruz
Shasun Pharma
Siemens
Sincamesp
Sinclair IS Pharma
Sindusfarma
Sistema Único de Saude (SUS)
Strides Arcolab
SulAmérica
Sun
Supera Farma Laboratorios
Takeda
Telefônica Digital
Tempo Participações
Teva Pharmaceutical industries
TKS Farmaceutica
Torrent
Toshiba
UCB
UERJ
UFMG
UFRJ
Uniao Quimica
UNICAMP
UNIFESP
Unimed Seguros
UnitedHealth
University of São Paulo
Valeant
Varian Medical Systems
Volta
Walgreens
Watson Pharmaceuticals (now Actavis)
Wheaton Brazil
Wockhardt
World Health Organization (WHO)
Zydus Cadila

To request an exec summary of this report please email Sara Peerun at [e-mail], Tel: [phone]

Or click on http://www.visiongain.com/Report/1157/Brazilian-Pharmaceutical-Market-2014-2024